Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (original) (raw)

Nature volume 461, pages 399–401 (2009)Cite this article

This article has been updated

Abstract

Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America[1](/articles/nature08309#ref-CR1 "World Health Organization. Hepatitis C. 〈 http://www.who.int/mediacentre/factsheets/fs164/en/

              〉 (2009)"). Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-α-2b (PegIFN-α-2b) or -α-2a (PegIFN-α-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the _IL28B_ gene, encoding interferon-λ-3 (IFN-λ-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry (_P_ \= 1.06 × 10\-25) and African-Americans (_P_ \= 2.06 × 10\-3). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Change history

The x-axis label in Figure 3 was corrected on 17 September 2009.

References

  1. World Health Organization. Hepatitis C. 〈http://www.who.int/mediacentre/factsheets/fs164/en/〉 (2009)
  2. McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580–593 (2009)
    Article CAS Google Scholar
  3. Muir, A. J., Bornstein, J. D. & Killenberg, P. G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 350, 2265–2271 (2004)
    Article CAS Google Scholar
  4. Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009)
    Article CAS Google Scholar
  5. Shiffman, M. L. et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126, 1015–1023; discussion 947 (2004)
    Article CAS Google Scholar
  6. Yan, K. K. et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J. Gastroenterol. 14, 3416–3420 (2008)
    Article Google Scholar
  7. Liu, C. H. et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 47, 1260–1269 (2008)
    Article CAS Google Scholar
  8. Wilson, J. F. et al. Population genetic structure of variable drug response. Nature Genet. 29, 265–269 (2001)
    Article CAS Google Scholar
  9. Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105, 7034–7039 (2008)
    Article ADS CAS Google Scholar
  10. McHutchison, J. G. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827–1838 (2009)
    Article CAS Google Scholar
  11. Robek, M. D., Boyd, B. S. & Chisari, F. V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79, 3851–3854 (2005)
    Article CAS Google Scholar
  12. Shiffman, M. L. et al. PEG-IFN-λ: antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection. J. Hepatol. 50 (suppl. 1), abstr. A643 s237 (2009)
  13. Kotenko, S. V. et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4, 69–77 (2003)
    Article CAS Google Scholar
  14. Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol. 4, 63–68 (2003)
    Article CAS Google Scholar
  15. Purcell, S. et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 81, 559–575 (2007)
    Article CAS Google Scholar
  16. Whitlock, M. C. Combining probability from independent tests: the weighted _Z_-method is superior to Fisher’s approach. J. Evol. Biol. 18, 1368–1373 (2005)
    Article CAS Google Scholar
  17. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nature Genet. 38, 904–909 (2006)
    Article CAS Google Scholar
  18. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20, 15–20 (1994)
    Article Google Scholar
  19. Ge, D. et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res. 18, 640–643 (2008)
    Article CAS Google Scholar

Download references

Acknowledgements

We are indebted to the IDEAL principal investigators, the study coordinators, nurses and patients involved in the study. We also recognize E. Gustafson, P. Savino, D. Devlin, S. Noviello, M. Geffner, J. Albrecht and A. C. Need for their contributions to the study. This study was funded by Schering-Plough Research Institute, Kenilworth, New Jersey. A.J.T. received funding support from the National Health and Medical Research Council of Australia and the Gastroenterological Society of Australia.

Author Contributions D.G., J.F., A.J.T. and J.S.S. contributed equally to this work. D.G., J.F. and A.J.T. performed the statistical and bioinformatical analyses. J.F. and A.J.T. defined the clinical phenotypes. K.V.S. performed the genotyping. D.B.G. and D.G. drafted the manuscript. J.S.S., J.G.M. and D.B.G. designed the study. All authors collected and analysed data and contributed to preparing the manuscript.

Author information

Authors and Affiliations

  1. Institute for Genome Sciences & Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA ,
    Dongliang Ge, Jacques Fellay, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen & David B. Goldstein
  2. Duke Clinical Research Institute and Division of Gastroenterology, School of Medicine, Duke University, Durham, North Carolina 27705, USA,
    Alexander J. Thompson, Andrew J. Muir & John G. McHutchison
  3. Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA ,
    Jason S. Simon, Ping Qiu & Arthur H. Bertelsen
  4. Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA ,
    Mark Sulkowski

Authors

  1. Dongliang Ge
    You can also search for this author inPubMed Google Scholar
  2. Jacques Fellay
    You can also search for this author inPubMed Google Scholar
  3. Alexander J. Thompson
    You can also search for this author inPubMed Google Scholar
  4. Jason S. Simon
    You can also search for this author inPubMed Google Scholar
  5. Kevin V. Shianna
    You can also search for this author inPubMed Google Scholar
  6. Thomas J. Urban
    You can also search for this author inPubMed Google Scholar
  7. Erin L. Heinzen
    You can also search for this author inPubMed Google Scholar
  8. Ping Qiu
    You can also search for this author inPubMed Google Scholar
  9. Arthur H. Bertelsen
    You can also search for this author inPubMed Google Scholar
  10. Andrew J. Muir
    You can also search for this author inPubMed Google Scholar
  11. Mark Sulkowski
    You can also search for this author inPubMed Google Scholar
  12. John G. McHutchison
    You can also search for this author inPubMed Google Scholar
  13. David B. Goldstein
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDavid B. Goldstein.

Ethics declarations

Competing interests

Competing Interests: J.G.M. and D.B.G. received research and grant support from Schering-Plough. J.G.M., A.J.M., M.S. and D.B.G. received consulting fees or acted in an advisory capacity for Schering-Plough. J.S.S., P.Q. and A.H.B. are employees of Schering-Plough. D.G., J.F., J.S.S., K.V.S., T.J.U., A.H.B. and D.B.G. are inventors of a patent application based on this finding.

Supplementary information

Supplementary Information

This file contains Supplementary Notes, Supplementary Tables S1-S8, Supplementary Box S1, Supplementary Figure S1 with Legend and Supplementary References. (PDF 440 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Ge, D., Fellay, J., Thompson, A. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature 461, 399–401 (2009). https://doi.org/10.1038/nature08309

Download citation

This article is cited by

Editorial Summary

Individual responses to hepatitis C virus

Hepatitis C is one of the most common infections in the world. Many of its estimated 170 million sufferers live with the disease for years with no serious symptoms, but in about one in four patients it leads to cirrhosis of the liver. The discovery of a biomarker that predicts an individual's response to hepatitis C treatment raises the possibility that clinical outcomes could be improved by raising patient compliance to the often demanding interferon treatment regime. The new marker is a 'single letter' genetic variant — a C (cytosine) replacing a T (thymidine) in a segment of DNA near the IL28B gene that encodes interleukin 28B (interferon-γ-3). This finding goes some way towards explaining the different treatment outcomes between individuals of European (high IL28B frequency), African and Asian ancestry. And importantly, it is of immediate clinical utility.

Associated content